home / stock / mdna:cc / mdna:cc news

MDNA:CC News and Press, Medicenna Therapeutics Corp. From 10/23/25

Stock Information
Company Name: Medicenna Therapeutics Corp.
Stock Symbol: MDNA:CC
Market: TSXC
Website: medicenna.com
Menu
MDNA:CC MDNA:CC Quote MDNA:CC Short MDNA:CC News MDNA:CC Articles MDNA:CC Message Board
Get MDNA:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
MDNA:CC - Updated MDNA11 Clinical Data from the ABILITY-1 Study to be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025

TORONTO and HOUSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, annou...
MDNA:CC - Medicenna Therapeutics Announces Participation in Upcoming Conferences

TORONTO and HOUSTON, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines for the treatment of cancer as well a...

MDNA:CC - ROTH to Host 4th Annual Healthcare Opportunities Conference on October 9 in New York City

NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- via IBN -- ROTH Capital Partners, LLC (“ROTH”), www.roth.com , is pleased to announce it will host the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, at the Metropolitan Club, New York City, NY...

MDNA:CC - Medicenna Therapeutics to Participate in the ROTH 4th Annual Healthcare Opportunities Conference

TORONTO and HOUSTON, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines for the treatment of cancer as well a...
MDNA:CC - Medicenna Announces Results of Annual Meeting of Shareholders

TORONTO and HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced the voting results ...

MDNA:CC - Medicenna to Participate at the H.C. Wainwright 27th Annual Global Investment Conference

TORONTO and HOUSTON, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage cancer immunotherapy company focused on the development of Superkines, announced today that Dr. Fah...

MDNA:CC - Medicenna Therapeutics Reports First Quarter Fiscal 2026 Financial Results and Operational Highlights

Updated cash guidance provides runway into at least the middle of calendar 2026 Company remains encouraged by MDNA11 clinical results presented to-date, demonstrating best-in-class potential of our IL-2 superkine by exceeding ORR benchmarks demonstrated with other competing therapies in s...
MDNA:CC - Medicenna Strengthens Intellectual Property Portfolio with Five Patents Granted for its IL-2 and IL-4 Superkines

TORONTO and HOUSTON, July 31, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing novel Superkines for oncology and autoimmune diseases, today announ...

MDNA:CC - Expected Canadian Company Earnings on Wednesday, July 30th, 2025

Tourmaline Oil Corp. (TOU:CA) is expected to report $0.91 for Q2 2025 Bausch Health Companies Inc. (BHC:CA) is expected to report $1.35 for Q2 2025 Information Services Corporation Class A Limited Voting Shares (ISC:CA) is expected to report for Q2 2025 Solitario Resources Corp. (SLR:...

MDNA:CC - Medicenna Therapeutics Reports Fiscal Year 2025 Financial Results and Operational Highlights

Updated cash guidance provides runway into at least mid-2026 MDNA11 Phase 1/2 clinical trial on track for data readouts in second half of the year as a single agent and in combination with KEYTRUDA ® at medical conferences and a planned KOL event MDNA11 continues to exhib...
Previous 10 Next 10